WEZENLA

Medicinal product

(Invented) name

WEZENLA

Active substance (s)

Ustekinumabas

Strength

130 mg

Pharmaceutical form

koncentratas infuziniam tirpalui

Route (s) of administration

leisti į veną

Legal status for supply

Receptinis

Narrow therapeutic index (NTI)

No

ATC code (s)

L04AC05, Ustekinumab

Marketing authorisation holder

Amgen Technology (Ireland) UC, Airija

Date of authorisation

2024-06-20

Date of renewal

Documents

Search in EMA Europe

Stage

Registruotas

Controlled?

No

Controlled substance type

Legal basis

10(4)

Procedure number

Marketing authorisation procedure

Centrinė registracija

Qualitative and quantitative composition

Flakone yra:	26 ml
Ustekinumabas	130 mg

Packages

PAKID	NPAKID	NPAKID-7	Pack type	Pack size	Type of packaging	Proposed dispensing/classification	Marketing authorisation no.	Supply status	From	To	Package is in foreign language	From	To	Mock-up
114010	100126	1100126	flakonas	26 ml N1		Receptinis	EU/1/24/1823/004	Netiekiama	-	-	No	-	-

Stadijos

Data	Stadija
2024-06-20	Registruotas